Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

What Is Anakinra? Is It Effective in Treating Covid-19?

What Is Anakinra? Is It Effective in Treating Covid-19?

Severe Covid-19 was present in 600 patients enrolled in a comprehensive clinical study. According to its data, patients at high risk of respiratory failure showed significant improvement after treatment with anakinra, the active ingredient in Kineret, compared with placebo.

What Is Anakinra?

Anakinra is used to treat children and adults with NOMID (neonatal-onset multisystem inflammatory disease = neonatal-onset multisystem inflammatory disease) and to reduce signs and symptoms and slow the progression of structural damage in moderate to severe active rheumatoid arthritis (RA). It is a recombinant protein medicine with FDA (US Food and Drug Administration) approval. It received its first FDA approval for NOMID in 2013. Anakinra binds to the widely expressed interleukin-1 (IL-1) receptor in many tissues and organs, and blocks the biological activity of IL-1. In both adults and children, IL-1 is an important mediator of inflammation and a driving force in autoinflammatory diseases.

Anakinra in the Treatment of Covid-19

Drugs that block IL-1 activity are being extensively tested in the treatment of severe Covid-19. In a smaller phase 2 human clinical study, anakinra had shown a 70% reduction in the risk of progression to severe respiratory failure (SRAS).

Previously, on June 24, 2021, the drug inhibiting the effect of interleukin 6 (IL-6), another trigger of inflammation, Actemra, containing tocilizumab, had received authorization to treat hospitalized patients receiving corticosteroids and needing non-invasive or invasive mechanical ventilation or supplemental oxygen via extracorporeal membrane oxygenation (ECMO). This was FDA “emergency use authorization” for adult and pediatric COVID-19 patients aged 2 years and older.

In Turkey, both Actemra, containing tocilizumab, and Kineret, containing anakinra, can be used to treat severe Covid-19 through an off-label use application to the Turkish Ministry of Health. Specialist doctors caring for hospitalized Covid-19 patients in serious condition can submit this application.

Previous research indicates that levels of soluble urokinase plasminogen activator receptor (suPAR) in the blood may be a biomarker indicating an increased risk of progression to severe Covid-19 and respiratory failure.

Supported by previous scientific studies, the SAVE-MORE study is an important confirmatory, double-blind, randomized controlled phase 3 clinical trial evaluating the efficacy and safety of starting anakinra treatment early in hospitalized patients with moderate or severe Covid-19.

Details of the Study

On September 3, 21, in Nature Medicine, researchers publishing the SAVE-MORE study identified 594 adults with Covid-19 who had been hospitalized at 37 centers in Greece and Italy and were at risk of progression to respiratory failure based on plasma suPAR levels of at least 6 ng/mL.

The primary objective was to evaluate the effect of early anakinra treatment on the clinical status of Covid-19 patients at risk of severe disease, using the 11-point WHO Clinical Progression Scale (WHO-CPS) 28 days after starting treatment. All patients received standard care consisting of physical symptom monitoring, regular pulse oximetry (blood oxygen level monitoring) and anticoagulation (blood thinning). Patients with severe disease according to the WHO definition were also given intravenous cortisone (dexamethasone) daily for 10 days. A total of 405 patients were randomized to receive anakinra and 189 to receive placebo. Approximately 92% of participants had severe pneumonia according to the WHO Covid-19 classification. The patients’ mean age was 62, and 58% were male. Their mean body mass index was 29.5 kg/m2.

Study Results

At 28 days, 204 patients (50.4%) treated with anakinra had fully recovered without detectable viral RNA, compared with 50 patients (26.5%) treated with placebo. In addition, significantly fewer patients in the anakinra group (13 patients, 3.2%) died within 28 days compared with patients in the placebo group (13 patients, 6.9%).

The median decrease in WHO-CPS scores from baseline to 28 days was 4 points in the anakinra group and 3 points in the placebo group. This was a statistically significant difference.

Laboratory follow-up data in those receiving anakinra showed:

  • A significant increase in absolute lymphocyte count on day 7
  • A significant decrease in circulating IL-6 levels on days 4 and 7
  • A significant decrease in plasma C-reactive protein (CPR) levels on day 7

Serious treatment-emergent adverse events were reported in 16% with anakinra and 21.7% with placebo; the most common adverse event was infection (8.4% with anakinra and 15.9% with placebo).

The next most common serious treatment-emergent adverse events were:

  • Ventilator-associated pneumonia
  • Septic shock and multiple organ dysfunction
  • Bloodstream infections
  • Pulmonary embolism

The most common treatment-emergent adverse events were:

  • Increases in liver function tests and hyperglycemia (similar in the anakinra and placebo groups)
  • An increase in nonserious anemia (lower in the anakinra group)

The researchers noted that several factors limited the study’s findings, including testing anakinra’s efficacy only in patients with critical Covid-19 and the lack of suPAR testing in all hospital settings. However, they said that "the results confirm the findings of the previous SAVE open-label phase 2 study”. The researchers concluded: “The results indicate that suPAR should be measured on admission in all Covid-19 patients who do not require oxygen or who require oxygen through nasal cannula or mask, and that anakinra treatment may be an appropriate option if suPAR levels are 6 ng/mL or higher.”

Cytokine Storm Syndrome Remains a Treatment Challenge

Randy Cron and Winn Chatham of the University of Alabama and Roberto Caricchio of Temple University in Philadelphia wrote in an editorial article as follows: “Many people who die from Covid-19 suffer from hyperinflammation with cytokine storm syndrome (CSS) and associated acute respiratory distress syndrome. The SAVE-MORE results are at odds with another recent canakinumab (Ilaris) trial, which showed no significant benefits compared with placebo in treating hospitalized patients with Covid-19 pneumonia. This randomized study yielded conflicting findings.”

"There are some important differences between these studies. One is that anakinra blocks both IL-1 Alpha and IL-1 Beta signaling, whereas canakinumab binds only IL-1 Beta. Endothelium infected with SARS-CoV-2 may be a particularly important source of IL-1 alpha that is not targeted by canakinumab."

The editorial authors said that additional studies had examined IL-6 inhibition to treat Covid-19 patients, but the data were inconsistent.

One thing that has become clear from this pandemic is that COVID-19-associated cytokine storm syndrome (CSS) is relatively unique, for example with only mildly elevated IL-6, CRP and ferritin levels. However, the SAVE-MORE study suggests that more targeted approaches, such as anakinra, "may allow earlier initiation of anticytokine therapy and support the use of IL-1 blockade with anakinra for cases of severe Covid-19 pneumonia.

Anticipated Risks for Severe Disease

Salim Hayek of the University of Michigan Frankel Cardiovascular Center clinic said:

"One of the greatest challenges in managing Covid-19 patients is identifying those at risk of severe disease who warrant early intervention with anti-inflammatory treatment. We and others have found that soluble urokinase plasminogen activator receptor (suPAR) levels are the strongest predictor of severe disease among inflammatory biomarkers. In this study, patients with high suPAR levels benefited from anakinra compared with placebo. This study is an excellent example of how suPAR levels can be used to identify high-risk patients who will benefit from therapies targeting inflammation. The findings are consistent with the hypothesis that patients with the highest degree of inflammation will benefit most from targeting the hyperinflammatory cascade with anakinra or other interleukin antagonists. Given that suPAR levels are the best predictors of high-risk disease, it is not surprising to see that patients with high levels benefit from targeting inflammation."

Hayek said that the message doctors should take away now is that anakinra effectively improves outcomes in COVID-19 patients with high suPAR levels.

"suPAR can be readily measured at the point of care. Therefore, a targeted strategy using suPAR to identify patients who will benefit from anakinra appears feasible. However, it is unclear whether anakinra is effective in patients with lower suPAR levels (<6 ng/mL), and this study has not answered that question. We eagerly await the results of other trials to make this determination. Whether suPAR levels can also guide the use of other treatments for Covid-19 should be investigated, and this may improve the personalization of Covid-19 treatment according to the underlying inflammatory state.”

Sources

1. Kyriazopoulou, E., Poulakou, G., Milionis, H. et al. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nat Med (2021). https://doi.org/10.1038/s41591-021-01499-z

2. Splete H. (07.09.2021). Anakinra Improved Survival in Hospitalized COVID-19 Patients. Medscape: https://www.medscape.com/

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

What Is Anakinra? Is It Effective in Treating Covid-19?

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy